Following on from information provided to NICE by the company, the appraisal of Breast cancer (advanced and/or metastatic) - sunitinib (in combination with capecitabine) was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 319 |
| Referral date | 01 March 2009 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
| 2nd appraisal committee meeting | TBC |
Project Team
| Assessment Group / Evidence Review Group: | TBC |
| Communications manager: | TBC |
| Executive Lead: | TBC |
| Project manager: | TBC |
| Technical Lead: | TBC |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 November 2022 | Discontinued. Following on from information provided to NICE by the company, the appraisal of Breast cancer (advanced and/or metastatic) - sunitinib (in combination with capecitabine) was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 5 April 2010 | The manufacturer of sunitinib has advised us that regulatory approval for this technology is not being sought at this time following the receipt of trial data. The Institute has therefore decided to remove this appraisal from its current work programme. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. If you have any comments or concerns please do not hesitate to contact the Project Manager for this appraisal, Cathryn Hall (020 7045 2240 or email: (cathryn.hall@nice.org.uk). |
| 23 September 2009 | Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid November 2010. The deadline for submissions is expected in approximately early February 2011. |
For further information on our processes and methods, please see our CHTE processes and methods manual